Literature DB >> 16989380

Sildenafil in management of persistent pulmonary hypertension of the newborn: report of two cases.

D E Simiyu1, C Okello, E G Nyakundi, A H Tawakal.   

Abstract

Persistent pulmonary hypertension of the newborn (PPHN) was described in 1969 by Gersomy and co-workers as persistent foetal circulation. Supra - systemic pulmonary artery pressures result in right to left shunting of blood through the ductus arteriosus and/or foramen ovale. This results from failure of the normal adaptation to extra uterine life of the foetal heart/lung system. The incidence is estimated at about 0.1-0.2% of live born infants, majority being term or post term. There is no race or gender related predisposition. Management was always difficult before the advent of nitric oxide (and now sildenafil). We report two newborn infants born at The Mater Hospital with perinatal asphyxia resulting inpersistent pulmonary hypertension that were successfully managed with sildenafil.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16989380     DOI: 10.4314/eamj.v83i6.9442

Source DB:  PubMed          Journal:  East Afr Med J        ISSN: 0012-835X


  2 in total

Review 1.  Sildenafil for pulmonary hypertension in neonates.

Authors:  Lauren E Kelly; Arne Ohlsson; Prakeshkumar S Shah
Journal:  Cochrane Database Syst Rev       Date:  2017-08-04

2.  Initial Experience with Sildenafil, Bosentan, and Nitric Oxide for Pediatric Cardiomyopathy Patients with Elevated Pulmonary Vascular Resistance before and after Orthotopic Heart Transplantation.

Authors:  Babak Daftari; Juan Carlos Alejos; Gregory Perens
Journal:  J Transplant       Date:  2010-03-10
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.